Form 4: Relay Therapeutics CEO Sells Shares for Tax Obligations
Insider Transaction Report
Relay Therapeutics President and CEO, Sanjiv Patel, sold 62,073 shares of common stock at $7 per share to cover tax withholding obligations related to RSU vesting.
Summary
- Sanjiv Patel, President and CEO, and Director of Relay Therapeutics, Inc. (RLAY), reported a transaction on November 3, 2025.
- Patel sold 62,073 shares of common stock at a price of $7 per share.
- The sale was non-discretionary, executed to cover income tax withholding obligations arising from the vesting of 136,853 Restricted Stock Units (RSUs) on October 31, 2025.
- Following the transaction, Patel directly owns 703,215 shares, which includes 136,854 shares underlying RSUs.
- Indirectly, 199,548 shares are held by The Patel Family Irrevocable Trust of 2019, and 687,355 shares by The SSP Irrevocable Trust of 2020. Patel disclaims beneficial ownership of these trust-held shares.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale of shares by an executive to cover tax withholding obligations upon RSU vesting, which is a common occurrence and does not reflect a change in sentiment regarding the company's prospects.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Power of Attorney | Sanjiv K. Patel granted a Limited Power of Attorney to Soo-Yeun Lim, Thomas Catinazzo, and William D. Collins to execute and file SEC forms (Form ID, 3, 4, 5, Schedule 13D) on his behalf as an officer and/or director of Relay Therapeutics, Inc. | October 17, 2025 | Streamlines the process for Sanjiv Patel to comply with SEC reporting requirements for his beneficial ownership of company securities, ensuring timely and accurate filings. |
Key Dates
| Date | Description |
|---|---|
| October 17, 2025 | Date of execution of Limited Power of Attorney by Sanjiv K. Patel. |
| October 31, 2025 | Vesting date of 136,853 Restricted Stock Units (RSUs) for Sanjiv Patel. |
| November 3, 2025 | Date of earliest transaction, specifically the sale of common stock by Sanjiv Patel. |
| November 4, 2025 | Signature date of the Form 4 by Soo-Yeun Lim, as Attorney-in-Fact for Sanjiv Patel. |
Recommendation
holdThe filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations upon RSU vesting. This transaction does not reflect a change in the company's fundamentals or the CEO's long-term outlook, and therefore, does not warrant a change in investment recommendation based solely on this report.
Keywords
Relay Therapeutics, RLAY, Sanjiv Patel, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.